View Financial HealthVaxxa 배당 및 자사주 매입배당 기준 점검 0/6Vaxxa 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-13.8%자사주 매입 수익률총 주주 수익률-13.8%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jun 17Vaxxa AB to Report Q2, 2026 Results on Jul 16, 2026Vaxxa AB announced that they will report Q2, 2026 results on Jul 16, 2026Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공고 • Mar 24Vaxxa AB to Report Q1, 2026 Results on Apr 22, 2026Vaxxa AB announced that they will report Q1, 2026 results on Apr 22, 2026공고 • Sep 24Vaxxa AB to Report Q3, 2025 Results on Oct 23, 2025Vaxxa AB announced that they will report Q3, 2025 results on Oct 23, 2025공고 • Jun 18Vaxxa AB to Report Q2, 2025 Results on Jul 17, 2025Vaxxa AB announced that they will report Q2, 2025 results on Jul 17, 2025공고 • Mar 25Vaxxa AB to Report Q1, 2025 Results on Apr 23, 2025Vaxxa AB announced that they will report Q1, 2025 results on Apr 23, 2025공고 • Jan 22Vaxxa AB to Report Fiscal Year 2024 Results on Feb 20, 2025Vaxxa AB announced that they will report fiscal year 2024 results on Feb 20, 2025Reported Earnings • Oct 17Third quarter 2024 earnings released: EPS: kr0 (vs kr0.035 loss in 3Q 2023)Third quarter 2024 results: EPS: kr0 (improved from kr0.035 loss in 3Q 2023). Revenue: kr22.4m (up 125% from 3Q 2023). Net income: kr7.0k (up kr806.0k from 3Q 2023). Profit margin: 0% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue.New Risk • Sep 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (29% average weekly change). Shareholders have been substantially diluted in the past year (over 17x increase in shares outstanding). Market cap is less than US$10m (€5.14m market cap, or US$5.72m).New Risk • Jul 21New major risk - Revenue and earnings growthEarnings have declined by 31% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 31% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 17x increase in shares outstanding). Market cap is less than US$10m (€3.53m market cap, or US$3.83m).Reported Earnings • Jul 18Second quarter 2024 earnings released: EPS: kr0.02 (vs kr0.87 loss in 2Q 2023)Second quarter 2024 results: EPS: kr0.02 (up from kr0.87 loss in 2Q 2023). Revenue: kr22.5m (up 123% from 2Q 2023). Net income: kr671.0k (up kr2.22m from 2Q 2023). Profit margin: 3.0% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue.공고 • Jun 18Vaxxa AB to Report Q2, 2024 Results on Jul 17, 2024Vaxxa AB announced that they will report Q2, 2024 results on Jul 17, 2024Reported Earnings • Apr 10First quarter 2024 earnings released: EPS: kr0.012 (vs kr1.00 loss in 1Q 2023)First quarter 2024 results: EPS: kr0.012 (up from kr1.00 loss in 1Q 2023). Revenue: kr21.1m (up 245% from 1Q 2023). Net income: kr312.0k (up kr2.97m from 1Q 2023). Profit margin: 1.5% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue.공고 • Apr 04Vaxxa AB to Report Q1, 2024 Results on May 03, 2024Vaxxa AB announced that they will report Q1, 2024 results on May 03, 2024공고 • Mar 26Vaxxa AB, Annual General Meeting, Apr 24, 2024Vaxxa AB, Annual General Meeting, Apr 24, 2024.New Risk • Mar 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 12x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr2.4m free cash flow). Share price has been highly volatile over the past 3 months (56% average daily change). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 12x increase in shares outstanding). Market cap is less than US$10m (€1.94m market cap, or US$2.11m).Reported Earnings • Feb 26Full year 2023 earnings released: kr0.002 loss per share (vs kr0.28 loss in FY 2022)Full year 2023 results: kr0.002 loss per share (improved from kr0.28 loss in FY 2022). Revenue: kr55.6m (up 22% from FY 2022). Net loss: kr5.10m (loss narrowed 90% from FY 2022).New Risk • Feb 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 12x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (100% average weekly change). Earnings have declined by 56% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 12x increase in shares outstanding). Market cap is less than US$10m (€2.11m market cap, or US$2.28m). Minor Risk Revenue is less than US$5m (kr41m revenue, or US$3.9m).공고 • Feb 07Vaxxa AB to Report Q3, 2024 Results on Mar 01, 2024Vaxxa AB announced that they will report Q3, 2024 results on Mar 01, 2024공고 • Jan 25Vaxxa AB to Report Fiscal Year 2023 Results on Feb 23, 2024Vaxxa AB announced that they will report fiscal year 2023 results on Feb 23, 2024공고 • Sep 28Vaxxa AB to Report Q3, 2023 Results on Oct 27, 2023Vaxxa AB announced that they will report Q3, 2023 results on Oct 27, 2023Reported Earnings • Aug 28Second quarter 2023 earnings released: kr0.01 loss per share (vs kr0.02 loss in 2Q 2022)Second quarter 2023 results: kr0.01 loss per share (improved from kr0.02 loss in 2Q 2022). Revenue: kr10.7m (down 19% from 2Q 2022). Net loss: kr1.55m (loss narrowed 61% from 2Q 2022).공고 • Jul 26Vaxxa AB to Report Q2, 2023 Results on Aug 24, 2023Vaxxa AB announced that they will report Q2, 2023 results on Aug 24, 2023공고 • May 22Augeo Group AB, Annual General Meeting, Jun 20, 2023Augeo Group AB, Annual General Meeting, Jun 20, 2023.Reported Earnings • May 22First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr6.42m (up 30% from 1Q 2022). Net loss: kr2.65m (loss narrowed 12% from 1Q 2022).Reported Earnings • Feb 22Full year 2022 earnings released: kr0.28 loss per share (vs kr0.20 loss in FY 2021)Full year 2022 results: kr0.28 loss per share (further deteriorated from kr0.20 loss in FY 2021). Revenue: kr46.9m (up kr45.5m from FY 2021). Net loss: kr51.1m (loss widened 303% from FY 2021).공고 • Jan 23Augeo Group AB to Report Fiscal Year 2022 Results on Feb 21, 2023Augeo Group AB announced that they will report fiscal year 2022 results on Feb 21, 2023Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Nov 02Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr12.7m (up kr11.5m from 3Q 2021). Net loss: kr6.71m (loss widened 308% from 3Q 2021).Reported Earnings • Aug 25Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr13.4m (up kr12.3m from 2Q 2021). Net loss: kr3.94m (loss widened 80% from 2Q 2021).Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공고 • Apr 04ESEN eSports AB, Annual General Meeting, May 02, 2022ESEN eSports AB, Annual General Meeting, May 02, 2022.Reported Earnings • Oct 31Third quarter 2021 earnings releasedThe company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: kr1.20m (up 459% from 3Q 2020). Net loss: kr1.82m (loss narrowed 18% from 3Q 2020).지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 7WA0 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 7WA0 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Vaxxa 배당 수익률 vs 시장7WA0의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (7WA0)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.8%업계 평균 (Entertainment)2.6%분석가 예측 (7WA0) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 7WA0 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 7WA0 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 7WA0 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 7WA0 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/15 06:37종가2026/07/15 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Vaxxa AB는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공고 • Jun 17Vaxxa AB to Report Q2, 2026 Results on Jul 16, 2026Vaxxa AB announced that they will report Q2, 2026 results on Jul 16, 2026
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공고 • Mar 24Vaxxa AB to Report Q1, 2026 Results on Apr 22, 2026Vaxxa AB announced that they will report Q1, 2026 results on Apr 22, 2026
공고 • Sep 24Vaxxa AB to Report Q3, 2025 Results on Oct 23, 2025Vaxxa AB announced that they will report Q3, 2025 results on Oct 23, 2025
공고 • Jun 18Vaxxa AB to Report Q2, 2025 Results on Jul 17, 2025Vaxxa AB announced that they will report Q2, 2025 results on Jul 17, 2025
공고 • Mar 25Vaxxa AB to Report Q1, 2025 Results on Apr 23, 2025Vaxxa AB announced that they will report Q1, 2025 results on Apr 23, 2025
공고 • Jan 22Vaxxa AB to Report Fiscal Year 2024 Results on Feb 20, 2025Vaxxa AB announced that they will report fiscal year 2024 results on Feb 20, 2025
Reported Earnings • Oct 17Third quarter 2024 earnings released: EPS: kr0 (vs kr0.035 loss in 3Q 2023)Third quarter 2024 results: EPS: kr0 (improved from kr0.035 loss in 3Q 2023). Revenue: kr22.4m (up 125% from 3Q 2023). Net income: kr7.0k (up kr806.0k from 3Q 2023). Profit margin: 0% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue.
New Risk • Sep 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (29% average weekly change). Shareholders have been substantially diluted in the past year (over 17x increase in shares outstanding). Market cap is less than US$10m (€5.14m market cap, or US$5.72m).
New Risk • Jul 21New major risk - Revenue and earnings growthEarnings have declined by 31% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 31% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 17x increase in shares outstanding). Market cap is less than US$10m (€3.53m market cap, or US$3.83m).
Reported Earnings • Jul 18Second quarter 2024 earnings released: EPS: kr0.02 (vs kr0.87 loss in 2Q 2023)Second quarter 2024 results: EPS: kr0.02 (up from kr0.87 loss in 2Q 2023). Revenue: kr22.5m (up 123% from 2Q 2023). Net income: kr671.0k (up kr2.22m from 2Q 2023). Profit margin: 3.0% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue.
공고 • Jun 18Vaxxa AB to Report Q2, 2024 Results on Jul 17, 2024Vaxxa AB announced that they will report Q2, 2024 results on Jul 17, 2024
Reported Earnings • Apr 10First quarter 2024 earnings released: EPS: kr0.012 (vs kr1.00 loss in 1Q 2023)First quarter 2024 results: EPS: kr0.012 (up from kr1.00 loss in 1Q 2023). Revenue: kr21.1m (up 245% from 1Q 2023). Net income: kr312.0k (up kr2.97m from 1Q 2023). Profit margin: 1.5% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue.
공고 • Apr 04Vaxxa AB to Report Q1, 2024 Results on May 03, 2024Vaxxa AB announced that they will report Q1, 2024 results on May 03, 2024
공고 • Mar 26Vaxxa AB, Annual General Meeting, Apr 24, 2024Vaxxa AB, Annual General Meeting, Apr 24, 2024.
New Risk • Mar 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 12x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr2.4m free cash flow). Share price has been highly volatile over the past 3 months (56% average daily change). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 12x increase in shares outstanding). Market cap is less than US$10m (€1.94m market cap, or US$2.11m).
Reported Earnings • Feb 26Full year 2023 earnings released: kr0.002 loss per share (vs kr0.28 loss in FY 2022)Full year 2023 results: kr0.002 loss per share (improved from kr0.28 loss in FY 2022). Revenue: kr55.6m (up 22% from FY 2022). Net loss: kr5.10m (loss narrowed 90% from FY 2022).
New Risk • Feb 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 12x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (100% average weekly change). Earnings have declined by 56% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 12x increase in shares outstanding). Market cap is less than US$10m (€2.11m market cap, or US$2.28m). Minor Risk Revenue is less than US$5m (kr41m revenue, or US$3.9m).
공고 • Feb 07Vaxxa AB to Report Q3, 2024 Results on Mar 01, 2024Vaxxa AB announced that they will report Q3, 2024 results on Mar 01, 2024
공고 • Jan 25Vaxxa AB to Report Fiscal Year 2023 Results on Feb 23, 2024Vaxxa AB announced that they will report fiscal year 2023 results on Feb 23, 2024
공고 • Sep 28Vaxxa AB to Report Q3, 2023 Results on Oct 27, 2023Vaxxa AB announced that they will report Q3, 2023 results on Oct 27, 2023
Reported Earnings • Aug 28Second quarter 2023 earnings released: kr0.01 loss per share (vs kr0.02 loss in 2Q 2022)Second quarter 2023 results: kr0.01 loss per share (improved from kr0.02 loss in 2Q 2022). Revenue: kr10.7m (down 19% from 2Q 2022). Net loss: kr1.55m (loss narrowed 61% from 2Q 2022).
공고 • Jul 26Vaxxa AB to Report Q2, 2023 Results on Aug 24, 2023Vaxxa AB announced that they will report Q2, 2023 results on Aug 24, 2023
공고 • May 22Augeo Group AB, Annual General Meeting, Jun 20, 2023Augeo Group AB, Annual General Meeting, Jun 20, 2023.
Reported Earnings • May 22First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr6.42m (up 30% from 1Q 2022). Net loss: kr2.65m (loss narrowed 12% from 1Q 2022).
Reported Earnings • Feb 22Full year 2022 earnings released: kr0.28 loss per share (vs kr0.20 loss in FY 2021)Full year 2022 results: kr0.28 loss per share (further deteriorated from kr0.20 loss in FY 2021). Revenue: kr46.9m (up kr45.5m from FY 2021). Net loss: kr51.1m (loss widened 303% from FY 2021).
공고 • Jan 23Augeo Group AB to Report Fiscal Year 2022 Results on Feb 21, 2023Augeo Group AB announced that they will report fiscal year 2022 results on Feb 21, 2023
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 02Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr12.7m (up kr11.5m from 3Q 2021). Net loss: kr6.71m (loss widened 308% from 3Q 2021).
Reported Earnings • Aug 25Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr13.4m (up kr12.3m from 2Q 2021). Net loss: kr3.94m (loss widened 80% from 2Q 2021).
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공고 • Apr 04ESEN eSports AB, Annual General Meeting, May 02, 2022ESEN eSports AB, Annual General Meeting, May 02, 2022.
Reported Earnings • Oct 31Third quarter 2021 earnings releasedThe company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: kr1.20m (up 459% from 3Q 2020). Net loss: kr1.82m (loss narrowed 18% from 3Q 2020).